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Abstract
Background and Purpose
Vessel graft failure is typically associated with arteriosclerosis, in which endothelial dysfunc-
tion/damage is a key event. Resveratrol has been shown to possess cardioprotective ca-
pacity and to reduce atherosclerosis. We aimed to study the influence of resveratrol on the
behavior of resident stem cells that may contribute to graft arteriosclerosis.
Experimental Approach
Vascular resident progenitor cells and embryonic stem cells were treated with resveratrol
under differentiating conditions and endothelial markers expression was evaluated. Expres-
sion of miR-21 and β-catenin was also tested and exogenously modified. Effects of resvera-
trol treatment in an ex vivo re-endothelialization model and on mice undergone vascular
graft were evaluated.
Key Results
Resveratrol induced expression of endothelial markers such as CD31, VE-cadherin and
eNOS in both progenitor and stem cells. We demonstrated that resveratrol significantly re-
duced miR-21 expression, which in turn reduced Akt phosphorylation. This signal cascade
diminished the amount of nuclear β-catenin, inducing endothelial marker expression and in-
creasing tube-like formation by progenitor cells. Both the inhibition of miR-21 and the knock-
down of β-catenin were able to recapitulate the effect of resveratrol application. Ex vivo,
progenitor cells treated with resveratrol produced better endothelialization of the decellular-
ized vessel. Finally, in a mouse model of vessel graft, a resveratrol-enhanced diet was able
to reduce lesion formation.
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Conclusions and Implications
We provide the first evidence that oral administration of resveratrol can reduce neointimal
formation in a model of vascular graft and elucidated the underpinning miR-21/Akt/β-catenin
dependent mechanism. These findings may support the beneficial effect of resveratrol sup-
plementation for graft failure prevention.
Introduction
Resveratrol (trans-3,4,5’-trihydroxystilbene) is a natural phytochemical also available as a die-
tary supplement, originally derived from grapes and naturally occurring in red wine and some
Asian medicinal herbs. Recent findings have reported a role for resveratrol in the so-called
‘French paradox’, the epidemiological observation of the relatively low incidence of cardiovas-
cular diseases in the high saturated fat-consuming French population. In this context, resvera-
trol has been shown to induce an anti-inflammatory phenotype in endothelial cells [1],
protecting them from apoptosis and reducing platelet and macrophages adhesion/extravasa-
tion [2]. Furthermore, low doses of resveratrol have been shown to enhance reendothelializa-
tion and to reduce neointima formation after endothelial injury by acting on endothelial nitric
oxide synthase (eNOS) expression and activity and endothelial progenitor cells homing [1,3].
To date, no study has reported the effect of resveratrol on the differentiation of vascular resi-
dent stem/progenitor cells.
Our group has previously isolated and characterized a population of vascular progenitor
cells that participate to the repopulation of the decellularized scaffold, used in our mouse
model of vessel graft. These cells express progenitor markers, such as Sca-1 and CD90 and are
able to give rise to both endothelial and smooth muscle cells in vitro [4]. Interestingly, recent
reports demonstrated that vessel wall progenitor cells contribute to neointimal formation in
vein grafts [5–7]. Typically, the insurgence of neointimal growth after vessel graft is initiated by
the loss of the endothelial layer, due to extensive cell death, which triggers inflammatory re-
sponse and vascular smooth muscle cell proliferation [8]. Studies from our group and others
have also demonstrated that damaged cells in vessel grafts can be replaced by blood and vessel-
derived progenitor cells [7,9]. In this process, the changes in micro-environmental clues (i.e.
VEGF) can modulate the differentiation of the resident progenitor cells and induce endothelial
differentiation, therefore reducing neointimal formation [4]. In this study, we propose a novel
mechanism of action for resveratrol in the context of graft atherosclerosis. Indeed, we estab-
lished that resveratrol is able to influence stem cell and resident progenitor cell fate, inducing
endothelial differentiation and therefore reducing neointimal formation. Furthermore, we ana-
lyzed the downstream pathway leading to endothelial differentiation and established that res-
veratrol acts through the inhibition of the miR21/Akt/β-catenin pathway.
Material and Methods
Detailed Material and Methods can be found in the online-only Supplement.
Cell culture
Mouse embryonic stem cells ES cell (ES-D3 cell line, CRL-1934; ATCC, Manassas, VA) were
cultured as previously reported [10]. Sca-1+ vascular resident progenitor cells were obtained as
previously described by spontaneous migration from decellularized vessel grafts collected 2
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weeks after implantation [4]. Differentiation was induced by plating cells on Collagen IV-coat-
ed flasks in presence of differentiation medium (DM) containing alpha DMEM (Gibco) sup-
plemented with 10% FBS (Gibco), 0.2mM 2-mercaptoethanol and 100u/ml penicillin and
100μg/ml streptomycin for 3 days, followed by 5 days of treatment with or without the addition
of 20μM resveratrol.
Decellularized vessel seeding
Decellularized vessel was prepared as previously described by isolating a mouse thoracic aorta
and treating it with SDS [4]. The vessel obtained was then seeded with 1×106 ESC differentiated
for 3 days in DM with or without the addition of 20μM resveratrol. Vessels were harvested
after 6 days of resveratrol or normal medium circulation.
Animal procedure and lesion measurement
Animal experiments were performed in accordance with UK and European legislation under
the Animals (Scientific Procedures) Act 1986 and European Directive 2010/63/EU and ap-
proved by King’s College London Institutional Animal Care and Use Committee. ApoE-/-
mice were fed with normal chow or RSV chow (0.02% in weight, calculated intake 24mg/kg/
day) for 7 days before venous graft was performed. Vein graft procedure was similar to that de-
scribed previously [11]. Animals were fed with resveratrol or control diet for additional two
weeks and lesion area was measured as described before [12].
Statistical analysis
Data are presented as mean±SEM and are representative of at least three independent experi-
ments. Student’s t-test was used to compare 2 samples, one-way ANOVA for multiple compar-
isons followed by pair-wise comparison.
Results
Resveratrol induces endothelial marker expression in stem/progenitor
cells
We tested the ability of resveratrol to induce endothelial marker expression in pre-differentiat-
ed embryonic stem cells. ESCs were plated on collagen IV for 3 days and then treated with res-
veratrol for further 5 days. Gene expression analysis showed that addition of resveratrol to the
culture medium induced the expression of endothelial markers such as CD31, VE-cadherin
and eNOS as compared to the control medium-treated cells (Fig 1A). Flow cytometry analysis
confirmed the increase in the percentage of cells positive for VE-cadherin and also showed an
increase in the number of cells expressing vascular progenitor markers, such as Sca-1 and c-Kit
(Fig 1B). Accordingly, we observed that the cells cultured in normal differentiation medium as-
sumed an elongated morphology typical of smooth muscle cells, while in presence of resvera-
trol they formed small colonies with cobblestone appearance, resembling endothelial cells
(Fig 1C and 1D).
Next, we examined the effect of resveratrol on the differentiation of the resident progenitor
cell population previously described by our group to be involved in the repopulation of a decel-
lularized vessel graft in vivo. These cells have been shown to express progenitor markers and to
be able to differentiate to both endothelial and vascular smooth muscle cells and to contribute
to neointima formation in a mouse model of graft [4]. We hypothesized that the differentiation
of these cells might influence the progression of the lesion. As previously described, graft-de-
rived resident progenitor cells expressed Sca-1 and mesenchymal markers, when cultured in
Resveratrol and Vascular Progenitors
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Fig 1. Effect of resveratrol on stem and progenitor cell marker expression. Embryonic stem cells (ESC, A-D) and vessel-derived progenitor cells (E-H)
were differentiated in the presence of 20μM resveratrol (RSV) for 5 days. In ESC, gene expression analysis showed increase in endothelial marker
Resveratrol and Vascular Progenitors
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non-differentiating conditions (S1 Fig). Treatment with resveratrol induced the expression of
endothelial markers in the progenitor cells, as shown at both gene expression and protein levels
(Fig 1E and 1F). Furthermore, resveratrol increased the ability of the progenitor cells to form
tube-like structure in an in vitro angiogenesis assay, as compared to control medium (Fig 1G).
Analysis of smooth muscle marker expression showed no difference at mRNA and promoter
activity level (S2 Fig).
In order to extrapolate the contribution of proliferation and cell death on the differentiative
effect of resveratrol, we cultured the graft-derived progenitor cells with or without resveratrol
and proceeded to measure cell number (proliferation), apoptosis (CaspaseGlo 3/7 activity). We
tested concentrations ranging from 5 to 100μM, including the concentration of 20μM that was
used in all the differentiation experiments. Results showed that cell number was unaffected be-
tween 5 to 20μM. Reduction in cell number was observed in presence of 100μM of resveratrol
(S3 Fig). Concomitantly, the activity of Caspase 3/7 was dramatically increased presence of
100μM of resveratrol, indicating cytotoxicity but remained unaffected in all other conditions
(S3 Fig).
Taken together, these results showed that 20μM resveratrol is able to induce markers of en-
dothelial differentiation in both stem and progenitor cells without substantial affecting their
proliferation and apoptosis.
Resveratrol reduces miR-21 expression regulating endothelial marker
expression
Resveratrol has been previously shown to regulate the expression of miR-21 in the context of
cancer cell growth and metastasis [13,14]. On the other hand, miR-21 is known to exert a role
in angiogenesis, although its effect seems to be context dependent [15,16]. We decided to study
the role of miR-21 in the resveratrol-dependent differentiation of the vascular resident progeni-
tor cells. Firstly, we studied the time course of miRNA-21 expression in cells treated with res-
veratrol and established that the expression level of miR-21 was reduced after resveratrol
treatment for up to 6 hrs (Fig 2A). In order to establish whether the modification of miR-21 ex-
pression plays a role in the differentiation, we overexpressed miR-21 using a precursor (pre-
21) or downregulated it using an inhibitor (inh-21). Transfected cells were cultured for 4 days
in collagen IV-coated plates to induce differentiation and endothelial marker expression and
tube formation capacity were assessed. Results showed that overexpression of miR-21 reduced
the levels of CD31 protein, while the inh-21 treatment had the opposite effect (Fig 2B). Inter-
estingly, inhibition of miR-21 increased the ability of progenitor cells to form tube-like struc-
tures in vitro, as compared to the control (Fig 2C–2E). Furthermore, we verified the tube-like
forming capacity of the progenitors after application of resveratrol with or without miR-21
overexpression. In vitro angiogenesis assay showed that in cells treated with the control pre-
miR, resveratrol increased the tube formation capacity (Fig 2F and 2G). The forced expression
of miR-21 sensibly reduced the tube-formation capacity of the progenitor cells, both in pres-
ence or absence of resveratrol (Fig 2H and 2I). Total tube length quantification confirmed the
observation that miR-21 reduces tube formation capacity of progenitor cells and blunts resver-
atrol-dependent increase in structure formation (Fig 2J).
expression CD31, VE-cadherin and eNOS, as compared to control medium (A). Flow cytometry analysis showed increased percentage of cells expressing
VE-cadherin and progenitor markers Sca-1 and c-Kit (B). Microphotographs showed the different morphology of cells cultured in differentiation medium
without (C) and with resveratrol (D). In vessel-derived progenitor cells treatment with resveratrol increased the gene expression of CD31 and VE-cadherin
and eNOS (E) as well as the protein levels of VE-cadherin (F), as compared to control. Tube formation capacity was increased by resveratrol treatment, as
compared to control (G). * p<0.05 and **p<0.01. Scale bars indicate 100μm.
doi:10.1371/journal.pone.0125122.g001
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Previous studies have demonstrated that miR-21 directly binds and induces the degradation
of phosphatase and tensin homolog (PTEN) mRNA, a well-known inhibitor of Akt
Fig 2. Inhibition of miR21 by resveratrol regulates induces endothelial marker expression. Treatment of the progenitor cells with resveratrol (RSV)
inhibited miR21 expression (A). Overexpression of miR21 (pre21) decreased CD31 protein level, as compared to the control transfected cells (preNC) (B).
MiR21 downregulation (inh21) increased CD31 expression, as compared to the negative control (inhNC) (B). Tube-formation was increased by Inh21 (D), as
compared to control treated cells (C), as confirmed by total tube length quantification (E). Representative pictures (F-I) and total tube length quantification (J)
showed that the resveratrol (RSV)-dependent increase in tube length was counteracted by miR-21 transfection. *p<0.05, **p<0.01 and ***p<0.001. Scale
bars indicate 50μm.
doi:10.1371/journal.pone.0125122.g002
Resveratrol and Vascular Progenitors
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phosphorylation [16]. We therefore analyzed the effect of resveratrol and miR-21 treatments
on the PTEN/Akt pathway. Cells were transfected with a plasmid bearing the luciferase report-
er gene under the control of the PTEN 3’UTR, which contains the miR-21 binding site. Follow-
ing the transfection, cells were treated with resveratrol and luciferase activity measured.
Analysis showed an increase in luciferase activity after resveratrol treatment, indicating a re-
duction in miR-21 binding to the promoter (Fig 3A). Consistently, gene expression levels of
PTEN were increased shortly after resveratrol stimulation (Fig 3B). Furthermore, we assessed
the levels of phosphorylation of Akt and established that treatment with resveratrol reduces
Akt phosphorylation after 60 min and this effect is maintained for 6hrs (Fig 3C). In presence of
mi-R21 overexpression, this pattern of phosphorylation was reverted and phosphorylation of
Fig 3. Resveratrol inhibits Akt pathway throughmiR21. Luciferase assay of the PTEN 3’UTR showed increased activity when vessel derived progenitor
cells were treated with resveratrol (RSV) for 48h, as compared to control (Vehicle, A). Gene expression analysis confirmed increased expression of PTEN
(B). Protein analysis indicated a reduction of phosphorylation of Akt after resveratrol treatment (C), this effect was reversed by miR21 overexpression (D),
*p<0.05.
doi:10.1371/journal.pone.0125122.g003
Resveratrol and Vascular Progenitors
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Akt resulted to be increase after 1 and 6 hours (Fig 3D). Therefore, these data demonstrated
that miR-21 expression and its downstream target PTEN/Akt pathway are altered by resvera-
trol treatment and are involved in the expression pattern of progenitor cells.
Effect of resveratrol on endothelial markers expression is mediated by
the inhibition of β-Catenin
Previous studies have shown that β-catenin is directly regulated by the Akt pathway [17] and
act as a mediator of resveratrol in the induction of chondrogenic differentiation of mesenchy-
mal stem cells [18]. We hypothesized the contribution of β-catenin in the context of endothelial
differentiation of vessel resident progenitor cells. Western blot analysis showed that resveratrol
treatment reduced the levels of active β-catenin in resident progenitor cells (Fig 4A). Addition-
ally, we observed that cells treated with the inhibitor of miR-21 showed reduced levels of active
β-catenin (Fig 4B). To study the effect of β-catenin in the differentiation process, we employed
lentiviral-mediated silencing that allowed for long term knockdown of β-catenin (S4 Fig). Mea-
surement of the expression of genes associated with differentiation at 3 and 7 days showed an
increase in CD31 expression after β-catenin silencing (Fig 4C) and an increase in VE-cadherin
protein expression (Fig 4D). Moreover, progenitor cells lacking β-catenin formed more tube-
like structures on Matrigel, as compared to the control-infected cells (Fig 4E). In order to con-
firm the contribution of β-catenin in the resveratrol-dependent EC marker expression, we
treated the progenitor cells with resveratrol and stimulated the canonical Wnt pathway by add-
ing LiCl. As shown in Fig 4F, stimulation of β-catenin pathway by LiCl blunted the effect of res-
veratrol on CD31 expression. Taken together, these results show that resveratrol and miR-21
modify β-catenin activation, subsequently affecting progenitor cell markers expression.
Resveratrol promotes endothelialization ex-vivo and reduces neointima
formation in a mouse model of vascular grafts
Our group has devised an ex-vivo model of vascular graft in which a decellularized vessel scaf-
fold can be repopulated by progenitor cells, using a bioreactor connected to a pump, providing
the medium flow [19]. We used this ex-vivo system to study the effect of resveratrol on in the
ability of stem cells to differentiate into endothelial cells and repopulate the intimal layer of the
decellularized vessel. Pre-differentiated embryonic stem cells were treated for 3 days with res-
veratrol or control medium and then placed in the circulation of the bioreactor in the presence
of resveratrol or control medium for additional 6 days. Vessels harvested were stained for the
endothelial marker CD31, showing the development of a continuous luminal endothelial layer
specifically in the vessel treated with resveratrol (Fig 5A and 5B). Staining for smooth muscle
marker SMA showed uniform distribution in the media of the repopulated vessels, indepen-
dently from the treatment (Fig 5C and 5D).
To further verify our hypothesis, we studied the effect of resveratrol in an in vivomodel of
arterial graft. The vena cava was grafted into the carotid artery of ApoE-/- mice, which were
fed normal chow or resveratrol containing diet, starting 7 days before the operation. Samples
were collected after 15 additional days of different diet and the formation of neointimal lesion
was quantified on sections obtained from formalin fixed grafts. Data showed that animals fed
with diet supplemented with resveratrol presented significantly reduced neointimal lesions, as
compared to mice fed with a normal diet (Fig 5C–5E). Furthermore, staining for CD31 showed
improved endothelial coverage in the resveratrol-fed animals (Fig 5F and 5G). Thus, we dem-
onstrated that resveratrol increased endothelialization in ex-vivo settings and reduced neointi-
mal formation in vivo after vessel graft, potentially through the increase of endothelial
differentiation and coverage.
Resveratrol and Vascular Progenitors
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Fig 4. Inhibition of β-catenin by resveratrol and inh21 enhances endothelial marker expression. Levels of activated β-catenin (ABC) were reduced by
resveratrol treatment (A). Transfection of vessel resident progenitor cells with miR21 inhibitor (inh21) decrease ABC expression, as compared to the negative
control (inhNC, B). No changes were associated with miR21 overexpression (pre21, B). Silencing of β-catenin by lentiviral infection (black bars) induced the
Resveratrol and Vascular Progenitors
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Discussion
Epidemiological studies have demonstrated a sensible discrepancy in the incidence of cardio-
vascular events in populations consuming a moderate amount of red wine [20,21]. This phe-
nomenon is referred as the ‘French paradox’ and has been partially attributed to the presence
of resveratrol in the red wine. While some of the mechanisms implicated in the effect of resver-
atrol in the context of cardiovascular diseases have been elucidated, no studies have reported
its effect on vessel resident progenitor cell differentiation. Resveratrol has been shown to reduce
thrombogenesis and atherogenesis in fat-fed hypercholesterolemic mice [22,23] and to im-
prove the outcome of aortic aneurysm by reducing inflammation and leukocyte infiltration
[24]. Furthermore, resveratrol was able to reduce neointimal formation after endothelial injury
through its protective effect on endothelial cell integrity [1,2]. In line with previously published
findings, in the present study we established that oral administration of resveratrol was able to
reduce the formation of neointimal lesions in the context of vascular graft model in ApoE-/-
mice. These results have an important clinical relevance for the use of resveratrol as a supple-
ment to improve vascular graft patency.
It was found that reduction of neointimal growth was associated with better endothelial cov-
erage and intact intimal layer. Following this observation, we propose a novel atheroprotective
mechanism for resveratrol, through the induction of endothelial differentiation of vessel resi-
dent progenitor cells. The promotion of a prompt protective endothelialization after grafting is
important for the positive long-term outcome of vessel graft, since it limits thrombogenesis
and stenosis. We studied the effect of resveratrol on Sca-1+ progenitor cells that were previous-
ly isolated and characterized by our group. Sca-1+ progenitors were shown to participate to
graft repopulation and to be prompted by local stimuli to differentiate into both vascular
smooth muscle and endothelial cells [4]. Indeed, we established that treatment of vascular resi-
dent progenitor cells with resveratrol increased their endothelial marker expression; these re-
sults were confirmed using mouse embryonic stem cells. The role of resveratrol in angiogenesis
has been mainly studied in the context of tumorigenesis, where it was shown to reduce capillary
formation by inhibiting the release of pro-angiogenic factors by cancer cells [25,26]. Interest-
ingly, recent papers have elucidated an important role of resveratrol in increasing the number,
viability and function of bone marrow endothelial progenitor cells [3,27,28]. It is of note that
we did not observe an overall effect of resveratrol on the vessel-derived progenitor cells prolif-
eration, as was previously observed for blood derived endothelial progenitor cells [28–30]. This
discrepancy might reflect the different nature of the two cell types, with bone marrow endothe-
lial progenitor cells committed almost exclusively to the endothelial lineage and therefore pro-
liferating to produce more endothelial cells, while the mesenchymal-like vessel-derived
progenitors are activated towards the endothelial differentiation pathway. Our results shed a
new light on the role of resveratrol on endothelial cell differentiation and function by demon-
strating its influence on vascular resident progenitor cells.
MiRNAs are short non-coding nucleotides that have recently been shown to regulate the ex-
pression of a large number of genes and have been therefore implicated in numerous physio-
logical and pathological processes, including differentiation, angiogenesis and atherosclerosis.
One of the most important observations in the present study is the finding of a novel mecha-
nism underlying the resveratrol-dependent induction of endothelial marker expression. In our
expression the endothelial marker CD31 (C), as compared to control virus (empty bars). β-catenin inhibition (Shβ) increased VE-cadherin protein level, as
compared to the control virus (ShCTL, D). Representative images showing the increase in tube-formation capacity of Shβ-catenin infected cells, as
compared to control cells (ShCTL, E). β-catenin activation by LiCl (50mM) was able to counteract resveratrol (RSV)-induced CD31 overexpression (F).
*p<0.05 and **p<0.01. Data are representative of three independent experiments. Scale bar indicates 50 μm.
doi:10.1371/journal.pone.0125122.g004
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Fig 5. Effect of resveratrol on ex vivo and in vivo re-endothelialization and neointimal formation. Embryonic stem cells were pre-differentiated for 3
days in the presence or absence of resveratrol and then seeded on a decellularized vessel in an ex-vivo bioreactor. The resveratrol treated cells were fed
Resveratrol and Vascular Progenitors
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system, treatment with resveratrol strongly reduced miR-21 expression, leading to increased
PTEN expression and reduced Akt phosphorylation. We also demonstrated that miR-21 over-
expression inhibited endothelial differentiation via the increase of Akt phosphorylation. Inter-
estingly, this pathway is the reverse of the TGFβ-induced endothelial-to-mesenchymal
transition, where TGFβ induces miR-21 and activates the Akt pathway, decreasing endothelial
marker expression [31]. This is quite remarkable considering the mesenchymal nature of the
described resident progenitor population. Moreover, these results are in accordance with previ-
ous studies on cancer cells showing inverse correlation between resveratrol and miR-21
[13,14], while miR-21 has been shown to reduce angiogenesis in mature endothelial cells [15].
More importantly, the aberrant overexpression of miR-21 has been shown to cause increase
with resveratrol-containing circulating medium, while the control cells were fed normal medium. Representative images showing the lack of endothelial
coverage on decellularized vessels infused ex vivo with stem cells differentiated in presence of control medium (A) as compared to the extensive re-
endothelialization observed with resveratrol-treated cells (B, CD31, white arrowheads). No difference was observed in SMA staining (C and D). ApoE-/- mice
were fed normal chow or resveratrol-chow for 7 days before undergoing vascular graft (n = 5 per group). Diet as continued for further 14 days and then graft
sections were stained and analyzed. Animal fed with resveratrol-chow showed reduced neointimal area within the graft, as compared to normal diet-fed
animals (E). Representative H&E images showed thicker neointimal layer in control (F, black arrow) as compared to resveratrol-treated animals (G).
Immunostaining for CD31 on the sections showed less endothelial staining from normal diet-fed animals (H). Animals fed with resveratrol-chow showed an
intact endothelial layer (I, CD31). DAPI, blue: nuclei. Scale bars: 25μm (A-D and H and I) and 200μm (F and G).
doi:10.1371/journal.pone.0125122.g005
Fig 6. Schematic representation of the mechanism proposed. In the system, resveratrol is shown to reduce miR-21 expression and leads to the
increased expression of phosphatase and tensin homolog (PTEN), Akt inhibitor. PTEN overexpression decreased Akt phosphorylation. In parallel, β-catenin
active form was reduced, either due to the reduction in Akt activity or through an independent pathway. Reduction of β-catenin and miR-21 inhibition both
affect the status of vascular resident progenitor cells, inducing their endothelial marker expression.
doi:10.1371/journal.pone.0125122.g006
Resveratrol and Vascular Progenitors
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neointimal formation in a rat model of balloon injury via PTEN inhibition [32]. In addition,
the results recently published by McDonald et al on the beneficial effect of miR-21 knockout in
a model of vessel graft complement and support our findings on the role of resveratrol in the
same model and confirm the central role played by miR-21 in this mechanism [33].
Previous work has demonstrated that Akt can directly activate β-catenin; the reduced acti-
vation of Akt observed after resveratrol treatment can therefore be at least partially responsible
for the detected diminished activation of β-catenin [34]. Inhibition of β-catenin via lentiviral-
mediated knockdown increased endothelial marker expression and tube-formation capacity in
the progenitor cell population, indicating a contribution of the β-catenin suppression to their
functional differentiation. In the present study, we have established that both the application of
resveratrol and the downregulation of miR-21 decreased Akt and β-catenin activation, thus
promoting differentiation in the progenitor cells. This finding is consistent with the previously
published papers showing that similar doses of resveratrol negatively regulate the activation of
β-catenin, reducing angiogenesis in mature endothelial cells and inhibiting cancer cell growth
[18,35]. The discrepancy of effects of resveratrol in different cell types can be explained by the
context-dependent function of β-catenin. Thus, the implication of β-catenin in the pathway
creates additional evidence of the link between resveratrol and miR-21 by providing a common
effector (Fig 6).
In summary, we established that resveratrol exert its role in directing stem/progenitor cell
differentiation towards endothelial lineages by inhibiting miR-21 and therefore reducing Akt
activation and β-catenin translocation. Resveratrol can also promote cell repopulation of a
decellularized vessel ex vivo and reduce neointimal formation in an in vivo model of vascular
graft. Therefore, the mechanisms elucidated in this work not only provides further insight in
the pharmacological action of resveratrol, but might also suggest new clinical applications in
vascular diseases where endothelial differentiation/coverage is affected.
Supporting Information
S1 Fig. Characterization of vascular resident progenitor cells. Representative images show-
ing the homogeneous expression of progenitor/mesenchymal markers CD34 (A), CD44 (B),
Sca1 (C) and CD90 (D).
(TIFF)
S2 Fig. Effect of resveratrol on smooth muscle marker expression. Vessel derived progenitor
cells were cultured in presence of resveratrol (RSV) for 5 days. Real time PCR showed no
changes in smooth muscle marker expression (A) and luciferase assay indicated no significant
difference in the activity of SMA promoter (B).
(TIFF)
S3 Fig. Effect of resveratrol treatment on progenitor cells growth and cells death. Progenitor
cells were treated with differentiation medium containing 0 to 100μM of resveratrol and tested
for proliferation (Alamar Blue, A) and apoptosis (CaspaseGlo 3/7, B). p<0.001.
(TIFF)
S4 Fig. Quantification of silencing efficiency. Representative real time PCR results showing
the effective knockdown of β-catenin (A) and the consequent downregulation of the down-
stream gene Axin2 (B) at day 3 and 7 after infection with silencing lentivirus (Sh beta catenin,
black columns) as compared to control (Sh control, white column).
(TIFF)
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S1 File. Supporting Materials and Methods. Additional materials and methods.
(PDF)
S1 Table. Supporting table. Primer sequences.
(PDF)
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